ABCL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abcellera Biologics Inc (ABCL) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are some positive aspects, such as the company's validated antibody discovery platform and a recent Buy rating from an analyst with a price target of $11, the financial performance and lack of significant trading signals suggest a cautious approach. The stock's recent technical indicators and options data also do not strongly support an immediate buy decision.
The MACD histogram is positive and expanding, suggesting bullish momentum. However, the RSI is in the neutral zone at 76.604, and moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 3.86), which could limit immediate upside potential.
The company has a validated antibody discovery platform with 19 molecules advanced into clinical trials. An analyst initiated coverage with a Buy rating and an $11 price target, which is significantly above the current price.
The company's financial performance in Q4 2025 showed a significant net income drop (-73.85% YoY) and EPS decline (-75.00% YoY), despite a revenue surge. There is no recent news or significant insider/hedge fund activity to act as a catalyst.
In Q4 2025, revenue increased by 788.18% YoY to $44.85M, but net income dropped by 73.85% YoY to -$8.94M, and EPS fell by 75.00% YoY to -0.03. Gross margin remained stable at 100%.
An analyst from JonesResearch initiated coverage with a Buy rating and a price target of $11, citing the company's strong capabilities and collaboration with Eli Lilly.
